Figure 3.

Observed and predicted plasma concentration-time profiles (median values) of clindamycin in patients with sensitive response in Group-I (fosmidomycin 900 mg plus 300 clindamycin every 6 hours for 3 days) and Group-II (fosmidomycin 1800 mg plus 600 mg clindamycin every 12 hours). The curve represents simulated concentration-time profile based on the median concentrations in each group.